What’s Next for Patients With Moderate-to-Severe UC When Conventionalsa Aren’t Enough?

5-ASA maintenance therapy may not deliver the relief that patients need1

graphic depicting 7 out of 10 patients who received 5-ASA therapy

7 out of 10 patients receiving 5-ASA therapy failed to achieve remission1b

Steroids can provide short-term relief, but patients may become over-reliant2,3

Steroids can provide short-term relief, but patients may become over-reliant

More than 1/3 of patients who filled steroids after UC diagnosis became steroid dependent2,3c

Even though advanced therapy may be recommended, patients often refuse biologics4

Stop icon

Almost 30% of patients deny or delay therapy due to concerns with biologics4d

After conventionals, start
with ZEPOSIA–
The only oral advanced therapy that can be used before biologics5-7

A non-biologic, small molecule with once-daily oral dosing.5

  • aIncludes 5-ASAs and corticosteroids.
  • bIn a systematic review of 11 RCTs published from 1987-2014, 71% (n=1107/1550) of patients with mild to moderate UC failed to enter clinical remission while taking 5-ASAs.1
  • cIn a retrospective cohort study from 2001-2011 of newly diagnosed patients with UC (N=464, 92% male) who received CS for a flare, 38% (n=175) of patients who required further CS therapy met criteria for CS dependency.2
  • dAs reported in the multinational 2019 GAPPS survey of patients with UC (n=1030), 78% of which self-reported as having moderate/severe disease. Data is representative of a subset of patients (n=319) who responded to the question regarding opting against IBD treatment. The IBD GAPPS survey was conducted by Adelphi Real World and supported by Bristol-Myers Squibb Company.4

5-ASAs=5 aminosalicylic acids; CS=corticosteroids; IBD=inflammatory bowel disease; RCTs=randomized controlled trials; UC=ulcerative colitis.

Explore the Efficacy
Data for ZEPOSIA

See if ZEPOSIA is Right for
Your Patients

This website is best viewed
using the horizontal display on
your tablet device.

This website is best viewed
using the vertical display on
your mobile device.